Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 73 citing articles:

Adenoviral vaccines—Infectious disease
Carly M. Bliss, Gerardo Montalvo Zurbia-Flores, Daniel Wright, et al.
Elsevier eBooks (2025), pp. 573-642
Closed Access
Towards new TB vaccines
Benedict Brazier, Helen McShane
Seminars in Immunopathology (2020) Vol. 42, Iss. 3, pp. 315-331
Open Access | Times Cited: 35
Vaccine development against tuberculosis before and after Covid-19
Stefan H. E. Kaufmann
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Tuberculosis Vaccines and T Cell Immune Memory
Fei Li, Wenrui Dang, Yunjie Du, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 483-483
Open Access | Times Cited: 4
Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2
Muralimanohara S. T. Murala, Vivek Gairola, Ekramy E. Sayedahmed, et al.
Vaccines (2025) Vol. 13, Iss. 4, pp. 406-406
Open Access
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
Anne Wajja, Beatrice Nassanga, Agnes Natukunda, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 3, pp. 285-296
Open Access | Times Cited: 9
Optimizing antigen selection for the development of tuberculosis vaccines
Yang Yang, Yizhen Chen, Tian Xia
Cell Insight (2024) Vol. 3, Iss. 3, pp. 100163-100163
Open Access | Times Cited: 3
Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis
Nitin Verma, Vimal Arora, Rajendra Awasthi, et al.
Journal of Drug Delivery Science and Technology (2022) Vol. 75, pp. 103690-103690
Closed Access | Times Cited: 15
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
Wenping Gong, Jingli Du
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 3, pp. 224-226
Open Access | Times Cited: 8
Racing to immunity: Journey to a COVID‐19 vaccine and lessons for the future
Ester Calvo Fernández, Lucie Y. Zhu
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 9, pp. 3408-3424
Open Access | Times Cited: 23
Tuberculosis Vaccines: An Update of Recent and Ongoing Clinical Trials
Sean Saramago, Joana Magalhães, Marina Pinheiro
Applied Sciences (2021) Vol. 11, Iss. 19, pp. 9250-9250
Open Access | Times Cited: 19
Antibodies as clinical tools for tuberculosis
Sophie McIntyre, Jeffrey Warner, C. M. Rush, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies
Hui Wang, Shuxian Wang, Fang Ren, et al.
Vaccines (2023) Vol. 12, Iss. 1, pp. 38-38
Open Access | Times Cited: 7
Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal
Rasoul Hoseinpour, Alka Hasani, Behzad Baradaran, et al.
Heliyon (2024) Vol. 10, Iss. 4, pp. e26193-e26193
Open Access | Times Cited: 2
In silico analysis for the development of multi-epitope vaccines against Mycobacterium tuberculosis
Jin-Seung Yun, A. Reum Kim, Soo Min Kim, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines
Virginie Rozot, Elisa Nemes, Hennie Geldenhuys, et al.
Communications Biology (2020) Vol. 3, Iss. 1
Open Access | Times Cited: 16
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
Hannah Sharpe, Nicholas M. Provine, Georgina Bowyer, et al.
JCI Insight (2022) Vol. 7, Iss. 6
Open Access | Times Cited: 10
The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19
Radostina Alexandrova, Pencho Beykov, Dobrin Vassilev, et al.
Biotechnology & Biotechnological Equipment (2020) Vol. 35, Iss. 1, pp. 74-102
Open Access | Times Cited: 15
Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases
Marwa Alhashimi, Ahmed Elkashif, Ekramy E. Sayedahmed, et al.
Viruses (2021) Vol. 13, Iss. 8, pp. 1493-1493
Open Access | Times Cited: 14
Therapeutic Potentials of Immunometabolomic Modulations Induced by Tuberculosis Vaccination
Bhupendra Singh Rawat, Deepak Kumar, Vijay Soni, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2127-2127
Open Access | Times Cited: 9
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults
Michael Riste, Julia L. Marshall, Iman Satti, et al.
Vaccines (2021) Vol. 9, Iss. 4, pp. 396-396
Open Access | Times Cited: 12
The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2 1-180 ) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge
Sergio Utrilla-Trigo, Luís Jiménez-Cabello, Eva Calvo-Pinilla, et al.
Journal of Virology (2021) Vol. 96, Iss. 3
Open Access | Times Cited: 12
Frontrunners in the race to develop a SARS-CoV-2 vaccine
Raquel Russell, Peter Pelka, Brian L. Mark
Canadian Journal of Microbiology (2020) Vol. 67, Iss. 3, pp. 189-212
Open Access | Times Cited: 12
The epidemiology of leprosy in Karonga District, northern Malawi 1973–2023: An analysis of leprosy’s distribution, risk factors, control and decline in rural Africa

Leprosy Review (2024) Vol. 95, Iss. 1, pp. 7-84
Open Access | Times Cited: 1
Randomized, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route
R Audran, Olfa Karoui, Laura Donnet, et al.
Journal of Infection (2024) Vol. 89, Iss. 2, pp. 106205-106205
Open Access | Times Cited: 1

Scroll to top